Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
K562/GM-CSF Vaccination in Combination with Imatinib Mesylate as Booster for Chronic Myeloid Leukemia Patients Previously Vaccinated on Protocol J0345
Protocol Number:
J0625
Phase:
Pilot
Physician:
B Douglas Smith
Purpose:
1.Determine whether a series of four K562/GM-CSF vaccinations (+/- imiquimod cream) can serve as an immunologic ?booster? and result in molecular remissions in subjects considered non-responders to imatinib mesylate + a primary series of K562/GM-CSF vaccines OR return subjects who have recurrent measurable disease after an initial complete molecular remission to imatinib mesylate + and a series of K562/GM-CSF vaccines to molecular negativity.
Eligibility:
Patients with AML who completed the entire protocol of J0345 and still ahve evidence of disease.
Treatment:
4 vaccines seperated by 3 weeks. Each vaccine will be given over 10 seperate injectiopn sites to the lower legs and upper arm.
Population:
Adult
Last Update
07/29/2014 04:02 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer